Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-04-18
2006-04-18
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100
Reexamination Certificate
active
07029679
ABSTRACT:
A variant of a LAV virus, designated LAVELIand capable of causing AIDS. The cDNA and antigens of the LAVELIvirus can be used for the diagnosis of AIDS and pre-AIDS.
REFERENCES:
patent: 4784941 (1988-11-01), Watanabe et al.
patent: 5034511 (1991-07-01), Alizon et al.
patent: 5869631 (1999-02-01), Alizon et al.
patent: 6337179 (2002-01-01), Alizon et al.
patent: 0 253 701 (1988-01-01), None
Wang, W.-K., et al., 1995, “The highly conserved aspartic acid residue between hypervariable regions 1 and 2 of human immunodeficiency virus type 1 gp 120 is important for early stages of virus replication”, J. Virol. 69(1):538-542.
Platt, E. J., et al., 1997, “Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor”, J. Virol. 71(2):883-890.
Chen, S. S.-L., et al., 1998, “Mutations in the leucine zipper-like heptad repeat sequence of human immunodeficiency virus type 1 gp41 dominantly interfere with wild-type virus infectivity”, J. Virol. 72(6):4765-4774.
Lee, Y.-M., et al., 1997, “Mutations in the matrix protein of human immunodeficiency virus type 1 inhibit surface expression and virion incorporation of viral envelope glycoproteins in CD4+ T lymphocytes”, J. Virol. 71(2):1443-1452.
Neurath et al., “Radioimmunoassay and enzyme-linked immunoassay of antibodies directed against lymphadenopathy-associated virus (LAV) proteins larger than the core portein (P24)”, J. Virological Methods, 12:85-92 (1985).
Wain-Hobson et al., “Nucleotide sequence of the AIDS virus, LAV”, Cell, 40:9-17 (1985).
Wong-Staal et al., “Genomic diversity of human T-lymphotropic virus type III (HTLV-III),” Science, 229:759-762 (1985).
Ellrodt et al., “Isolation of Human T-lymphotropic Retrovirus (LAV) from Zairian married couple, one with AIDS, one with prodomes,” The Lancet, 1383-1385 (1984).
Ratner et al., “Complete nucleotide sequence of the AIDS virus, HTLV-III,” Nature, 323:277-285 (1985).
Sanchez-Pesdador et al., “Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2),” Science 227:484-492 (1985).
Muesing et al., “Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus,” Nature, 313:450-458 (1985).
Alizon et al., “Molecular cloning of lymphadenopathy-associated virus,” Nature, 312:757-760 (1984).
Nature, 313:277-284 (1985).
Goodenow et al., J. Acquir. Immune Defic. Syndr., 2:344-352 (1989).
Gao et al., J. Virol. 68:7433-7447 (1994).
Alizon Marc
Montagnier Luc
Sonigo Pierre
Wain-Hobson Simon
Finnegan Henderson Farabow Garrett & Dunner LLP
Institut Pasteur
Parkin Jeffrey S.
LandOfFree
Variant of LAV viruses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Variant of LAV viruses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Variant of LAV viruses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3572061